

- Okuda staging, of hepatocellular carcinoma, 546, 546t
- Olanzapine
for acute alcohol intoxication, 2727
adverse effects of, 2721, 2722t
for bipolar disorder, 2718
for delirium, 64, 64t, 65
for nausea and vomiting, 61, 261
overdosage/poisoning with, 473e-8t
for schizophrenia, 2721, 2722t
- Olecranon bursitis, 2247
- Olfactory bulb, 211, 212f
- Olfactory disorders, 214
diseases and conditions associated with, 214–215, 214t
epidemiology of, 214, 214f
etiology of, 214, 214t
evaluation of, 215–216
in gonadotropin deficiency, 2363, 2364t
head injury and, 457e-2
taste disorders and, 215
treatment of, 216–217
- Olfactory nerve, 2537
- Olfactory system, 211–212, 212f
- Olig 2* gene, 444e-5
- Oligoastrocytomas, 601
- Oligodendrocyte myelin glycoprotein (OMGP), 444e-8
- Oligodendroglioma, 600–601
- Oligomenorrhea, 335, 337f, 2355
- Oligomer(s), 444e-9
- Oligopotent stem cells, 454, 454f
- Oliguria, 292, 1729, 1755
- Olivopontocerebellar atrophy. *See* Spinocerebellar ataxia (SCA), SCA1
- Ollier's disease (enchondromatosis), 426e-7, 594
- Olmesartan, 269
- Olsalazine, 1959, 1959t
- Omacetaxine, 691, 691t
- Omalizumab
adverse effects of, 372e-30, 377
for allergic rhinitis, 372e-30, 2124
for asthma, 1678, 1680
for urticaria, 2119, 2120
- Omapatrilat, 1513
- Omecamtiv mecarbil, 1510, 1510t
- Omega-3 fatty acids (fish oils)
adverse effects of, 2447, 2448t
antiplatelet effects of, 404
in enteral nutrition formulas, 98e-5
for heart failure, 1513
for hypertriglyceridemia, 2447, 2448t
for metabolic syndrome, 2454
- Omenn syndrome, 2108–2109
- Omentectomy, 593
- Omeprazole
action of, 1920
formulations of, 1920
for gastrinoma, 2337
genetic variations in response to, 39t, 40
for GERD, 263
in *H. pylori* eradication, 1042t, 1922, 1922t
for high-altitude cough, 476e-4
metabolism of, 34t, 40
for peptic ulcer disease, 1920–1921, 1920t
for ZES, 1929
- OMGP (oligodendrocyte myelin glycoprotein), 444e-8
- OmpA protein, 1036
- Omsk hemorrhagic fever virus, 1307t, 1322
- OMVs (outer-membrane vesicles), 1002, 1002f
- Onchocerca volvulus*/onchocerciasis
characteristics of parasite, 1418t, 1420
clinical features of
lymph nodes, 1421
ocular, 1421
onchocercomatous, 1420–1421
skin, 357, 357t, 829, 1420, 1421f
systemic, 1421
diagnosis of, 245e-3t, 245e-6t, 765t, 1421
epidemiology of, 765t, 1418t
etiology of, 1420
pathogenesis of, 1420
prevention of, 1421
treatment of, 246e-9, 1421
- Oncocytic tumors, renal, 578, 578t
- Oncogene(s)
activation of, 101e-2–3, 101e-7f
definition of, 101e-1–2, 102e-1
in human cancers, 101e-1–2, 101e-2t. *See also* Cancer genetics
in lymphoid malignancies, 699t
signaling pathways, 102e-11f
- Oncogene addiction, 102e-6, 102e-7
- Oncogene checkpoint, 102e-2f
- Oncologic emergencies. *See* Cancer, emergencies in
- Oncology, 103e-2
- Oncolytic viruses, 91e-4
- Oncostatin M (OSM), 372e-11t
- Ondansetron
for ataxia/tremor, 2672
for carcinoid syndrome, 566
for ciguatera poisoning, 2742
for nausea and vomiting, 62, 103e-25, 109, 259, 260t, 474
for scorpion poisoning, 2744
- Ondine's curse, 1722
- One-and-a-half syndrome, 210
- "Onion skinning," 1865
- Online Mendelian Inheritance in Man*, 425, 426t
- Onycholysis, 348, 351, 380
- Onychomadesis, 380
- Onychomycosis, 350, 1343, 1357, 1358t
- O'nyong-nyong virus infection, 837, 1306t, 1313
- Oocyte donation, 85e-9, 85e-10f, 337
- Oogonia, 2375, 2375f
- Oophorectomy, 103e-3, 530t, 592, 594
- Opa protein, 1003
- OPC-31260, 1853
- OPC-67683 (delamid), 205e-7
- Open-access endoscopy, 1900
- Operational taxonomic units (OTUs), 86e-2
- OPG. *See* Osteoprotegerin (OPG)
- Ophthalmia neonatorum, 1006, 1009t
- Ophthalmomyiasis, 2747
- Ophthalmopathy
diabetic. *See* Diabetic retinopathy
Graves'. *See* Graves' ophthalmopathy
thyroid-associated, 2294
- Ophthalmoplegia
internuclear, 209–210, 210f
neuromuscular causes of, 462e-2t
progressive external. *See* Progressive external ophthalmoplegia
video library, 41e-1v
- Ophthalmoscopy, 40e-1, 40e-2, 40e-2t
- Opioid(s)
action of, 92, 444e-4, 465e-3, 465e-3f, 465e-5t
adverse effects of, 61, 468e-1, 2232t
delirium, 168
hypogonadism, 2364
management of, 92
pruritus, 381
respiratory depression, 92
for back pain, 119
COX inhibitor combinations, 92–93
cross-tolerance among, 60
dosage of, 60
for dyspnea, 62
endogenous, 89
for frostbite, 478e-4
in mechanical ventilation, 1741
for migraine, 2592t, 2593
most commonly abused, 468e-1. *See also* Opioid use disorders
neurobiology of, 468e-1, 468e-1t, 468e-2f
for osteoarthritis, 2232, 2232t
overdosage/poisoning with, 468e-3, 468e-3t, 473e-3, 473e-13t, 1773
for pain, 60–61, 91t, 92, 94, 94t
pharmacology of, 468e-1–3
for restless legs syndrome, 192
routes of administration of, 92
systems effects of, 468e-2
withdrawal from, 468e-3
- Opioid receptors, 89, 468e-1, 468e-1t, 468e-2f
- Opioid use disorders, 468e-1
clinical features of, 468e-2
complications of, 468e-2
diagnosis of, 468e-1
epidemiology of, 468e-1
pathogenesis of, 465e-3, 465e-3f
prevention of, 468e-4
in terminally ill patient, 61
treatment of, 468e-3–4, 468e-3t
- Opisthorchis*/opisthorchiasis, 552, 765t, 1428, 1428t. *See also* Biliary (hepatic) flukes
- Oppenheim's dystonia, 2620
- Oprelvekin (IL-11), 103e-24
- Opsoclonus, 211
- Opsoclonus-mycoclonus syndrome, paraneoplastic, 372e-25t, 614t, 618
- Opsonization, 372e-3
- Optical coherence tomography (OCT), 1465, 1465f, 1668
- Optic ataxia, 181
- Optic atrophy, 203, 203f, 1136
- Optic chiasm, 197
- Optic cup, 205, 205f
- Optic disc
anatomy of, 40e-1
damage to, 197
drusen, 203–204, 203f
edema, 203
normal, 40e-1, 40e-1f
swelling of, 40e-5, 40e-5f
vascular sheathing over, 40e-4, 40e-4f
- Optic gliomas, 2264
- Optic nerve, 195
disorders of, 197–199. *See also* Optic neuritis;
Optic neuropathy
examination of, 2537
injuries of, 457e-2
tumors of, 206–207
- Optic neuritis, 196
color desaturation in, 197
epidemiology of, 202
ethambutol-related, 205e-4
in MS, 202, 2663
in neuromyelitis optica, 2656
paraneoplastic, 614t, 619
recurrent, 202
retrobulbar, 196, 202, 202f
in sarcoidosis, 2208
treatment of, 202
visual field defects in, 197
- Optic neuropathy
anterior ischemic, 202, 202f
drug-induced, 203
Leber's. *See* Leber's hereditary optic neuropathy (congenital amaurosis)
posterior ischemic, 202
toxic, 203, 203f
- Optokinetic reflex, 195
- Oral cancer
clinical features of, 46e-3f, 46e-4f, 239t, 503
diagnosis of, 237
incidence of and deaths from, 467t
prevention of, 476
risk factors for, 237, 2725
smoking and, 476
- Oral cavity. *See also* Oral mucosa
anaerobic bacterial infections of, 1095, 1097, 1102
anaerobic flora of, 1094–1095, 1095t
cancer treatment effects in, 623
F. tularensis infection of, 1068
infections of, 233–234, 487
in nutritional deficiencies, 463t
systemic disease signs in, 46e-1, 235
- Oral cholecystography (OCG), 2078
- Oral contraceptives, 2390
for acne vulgaris, 352
adverse effects of, 2391t
cholestasis, 284, 2025t, 2029
cutaneous, 132t, 352, 353, 366, 379
hair loss, 380
hepatotoxicity, 2025, 2027
hirsutism, 380